PHP
NVRO

Parkman Healthcare Partners’s NEVRO CORP. NVRO Stock Holding History

Parkman Healthcare Partners’s Portfolio NVRO Stock Details NVRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35,792
Closed -$5.93M – 84
2021
Q2 		$5.93M Buy
+35,792
New +$5.59M 1.3% 27

Other funds holding NVRO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parkman Healthcare Partners's NVRO Position: Q3 2021 in Review

Parkman Healthcare Partners sold out of NEVRO CORP. (NVRO) in Q3 2021, closing a stake of 35,792 shares — an estimated $5.93M sold.

Parkman Healthcare Partners first reported a position in NVRO in Q2 2021 and held it in 1 quarter. The position peaked at $5.93M in Q2 2021. 194 funds tracked by Wall St. Rank hold NVRO as of Q3 2021.

  • Parkman Healthcare Partners reported no remaining NEVRO CORP. position as of Q3 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 35,792 NEVRO CORP. shares in Q3 2021, an estimated $5.93M.
  • Parkman Healthcare Partners first reported a position in NEVRO CORP. in Q2 2021 and held it in 1 quarter.
  • Parkman Healthcare Partners's NEVRO CORP. position peaked at $5.93M in Q2 2021.
  • 194 funds tracked by Wall St. Rank held NEVRO CORP. as of Q3 2021.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.